neuroscience

R&D

Clinical Trials Round-Up: July/August 2026

While the volume of announcements hit a mid-year slump, July and August still produced an exciting array of updates across the drug development arena.

R&D

Clinical Trials Round-Up: May and June 2026

May and June delivered a plethora of clinical trial updates. In the build-up to ASCO in June, our inbox was overflowing with oncology trial results.

News

GSK makes fresh neuroscience foray with £2bn+ ABL deal

Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting.

R&D

Partner Content

Neuroscience Innovation Pharma Partnering Summit

Significant breakthroughs in CNS biology, coupled with innovative neuroscience technologies and a more supportive regulatory landscape, have fuelled increased investment and pharmaceutical interest

News

Lundbeck president and CEO Charl van Zyl

Lundbeck planning for four novel drugs in phase 3 in 2026

Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from

News

Seaport docks $225m for its improved neuropsychiatry drugs

After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved swiftly to shore up its finances with a $225 million second round to fund the developme

Clinical Trials Round-Up: July/August 2026

Clinical Trials Round-Up: May and June 2026

GSK makes fresh neuroscience foray with £2bn+ ABL deal

Neuroscience Innovation Pharma Partnering Summit

Lundbeck planning for four novel drugs in phase 3 in 2026

Seaport docks $225m for its improved neuropsychiatry drugs

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

neuroscience

Editor's Picks